Skip to content
MARKETS / BALCAO / PETV
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

PetVivo Holdings, Inc. PETV

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.1M
▲ 0.8% YoY
$-10.5M
$-6.1M
In brief

What this company does

The Company has a pipeline of seventeen products for the treatment of animals and humans. A portfolio of ten issued patents (consisting of six U.S. patents and four foreign patents), two U.S. patent applications, and six proprietary trade secrets protects the Company’s biomaterials, products, production processes and methods of use. The Company began commercialization of its lead product Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses, in the second quarter of its fiscal year ended March 31, 2022. In connection with the Public Offering, the Company’s common stock and warrants were registered under Section 12(b) of the Exchange Act and began trading on The Nasdaq Capital Market, LLC under the symbols “PETV” and “PETVW,” respectively. The Company operates as one segment from its corporate headquarters in Edina, Minnesota. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals such as cats, dogs and horses.

Written from the business description in PetVivo Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 June 2026. Every sentence was checked against that document before publication.

Growth
USD 1.1M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.1 · Net income -10.5
-8M-16M200920112014201620182020202220242025
Compound annual growth
+7.6%
+146.4%
+31.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +146.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−917 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -793.9% · Net -917.4%
-100000%-200000%200920112014201620182020202220242025
ROE
FY2025 · ROE -326.3%
-5000%-10000%200920112014201620182020202220242025

Each USD of equity lost 326 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -6.1
-4M200920112014201620182020202220242025

Total assetsUSD 3.6M
EquityUSD 2.2M
Gross debtUSD 321,447.00
Current ratio1.35×

Equity funds 61% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142012201120102009
Revenue $B0.00.00.00.00.00.00.0·0.00.00.0··0.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0····
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·····
Income tax $B················
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0······
EPS, diluted $−0.38−0.41−0.78−0.85·−0.57−0.39−0.26−0.14−1.73−0.46−0.21····
Dividend / sh $················
Payout %················
ROE %−326.3−342.5−1552.9−259.8−197.1···−488.8−4409.2−10405.6−970.9····
Shares out B0.040.020.020.010.010.010.010.020.020.010.010.010.190.110.11·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 67 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 28 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivitySurgical & Medical Instruments & Apparatus
Listed onOTC market
Incorporated inNevada
Fiscal year endsMarch 31
SEC categoryemerging growth company
Data on record since2009

Share this section

Download image